Raymond James Financial’s Dianthus Therapeutics DNTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$459K Buy
5,210
+872
+20% +$90.5K ﹤0.01% 4614
2026
Q2
$423K Sell
4,338
-10,750
-71% -$939K ﹤0.01% 4624
2026
Q1
$1.27M Buy
+15,088
New +$874K ﹤0.01% 3694
2025
Q4
– Sell
-11,245
Closed -$442K – 5205
2025
Q3
$442K Buy
11,245
+9,815
+686% +$251K ﹤0.01% 4185
2025
Q2
$26.6K Buy
+1,430
New +$26.8K ﹤0.01% 5468

Other funds holding DNTH

Raymond James Financial's DNTH Position: Q3 2026 in Review

Raymond James Financial increased its Dianthus Therapeutics (DNTH) stake by 20% in Q3 2026, buying an estimated $90.5K and bringing the position to 5,210 shares worth $459K. The position accounts for ﹤0.01% of the portfolio, ranked #4614.

Raymond James Financial first reported a position in DNTH in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.27M in Q1 2026. 275 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • Raymond James Financial held 5,210 shares of Dianthus Therapeutics worth $459K as of Q3 2026.
  • Raymond James Financial bought 872 Dianthus Therapeutics shares in Q3 2026, an estimated $90.5K.
  • Dianthus Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #4614 holding.
  • Raymond James Financial first reported a position in Dianthus Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Raymond James Financial's Dianthus Therapeutics position peaked at $1.27M in Q1 2026.
  • 275 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.